BACKGROUND: Myocardial perfusion imaging with dipyridamole is an alternative with which to evaluate patients who are unable to exercise. Many patients who undergo dipyridamole testing are limited in their ability, but are not completely unable, to exercise. There are benefits from adding low workload exercise to dipyridamole testing, including a reduction of thallium 201 concentration in the liver, leading to a higher heart-to-liver activity ratio and better image quality. This prospective study was designed to evaluate a protocol of exercise supplementation during dipyridamole technetium 99m sestamibi imaging and to verify whether a higher heart-to-liver activity ratio could be obtained. We also evaluated the potential of this combined protocol to prevent hypotension and induce ischemic changes on the electrocardiogram (ECG). METHODS AND RESULTS: Ninety consecutive patients who were not completely disabled for exercise underwent dipyridamole Tc-99m sestamibi cardiac single photon emission computed tomography with a protocol of exercise supplementation (DipEx). The heart-to-liver activity ratio, hemodynamics, and electrocardiographic changes were studied. The findings were compared with those of a control group (Dip) composed of 99 patients who underwent dipyridamole infusion alone. Patients with left bundle branch block, pacemaker, and atrial fibrillation were excluded. The DipEx patients tolerated the protocol, exercising 4.2 +/- 1.3 minutes on the treadmill (Bruce protocol). Compared with Dip, patients in the DipEx group had a higher heart-to-liver activity ratio (1.3 +/- 0.4 vs 1.6 +/- 0.5, respectively; P =.00001), had no incidence of hypotension (6% vs 0%, respectively; P =.03), and had a higher sensitivity of the ECG to detect ischemia (6% vs 34%, respectively; P =.003). The increase in sensitivity seen in the DipEx group was accompanied by a significant decrease in specificity compared with the Dip group (67% vs 100%, P =.000001). CONCLUSIONS: Our data show that the addition of limited exercise to dipyridamole results in benefits during Tc-99m sestamibi imaging, increasing heart-to-liver activity ratio, preventing vasodilator-induced hypotension, and improving ECG sensitivity for the detection of ischemia. Furthermore, this protocol also provides an estimation of the patient's physical capacity and could be used as an alternative for patients undergoing dipyridamole infusion who are not completely unable to exercise.
BACKGROUND: Myocardial perfusion imaging with dipyridamole is an alternative with which to evaluate patients who are unable to exercise. Many patients who undergo dipyridamole testing are limited in their ability, but are not completely unable, to exercise. There are benefits from adding low workload exercise to dipyridamole testing, including a reduction of thallium 201 concentration in the liver, leading to a higher heart-to-liver activity ratio and better image quality. This prospective study was designed to evaluate a protocol of exercise supplementation during dipyridamole technetium 99m sestamibi imaging and to verify whether a higher heart-to-liver activity ratio could be obtained. We also evaluated the potential of this combined protocol to prevent hypotension and induce ischemic changes on the electrocardiogram (ECG). METHODS AND RESULTS: Ninety consecutive patients who were not completely disabled for exercise underwent dipyridamole Tc-99m sestamibi cardiac single photon emission computed tomography with a protocol of exercise supplementation (DipEx). The heart-to-liver activity ratio, hemodynamics, and electrocardiographic changes were studied. The findings were compared with those of a control group (Dip) composed of 99 patients who underwent dipyridamole infusion alone. Patients with left bundle branch block, pacemaker, and atrial fibrillation were excluded. The DipExpatients tolerated the protocol, exercising 4.2 +/- 1.3 minutes on the treadmill (Bruce protocol). Compared with Dip, patients in the DipEx group had a higher heart-to-liver activity ratio (1.3 +/- 0.4 vs 1.6 +/- 0.5, respectively; P =.00001), had no incidence of hypotension (6% vs 0%, respectively; P =.03), and had a higher sensitivity of the ECG to detect ischemia (6% vs 34%, respectively; P =.003). The increase in sensitivity seen in the DipEx group was accompanied by a significant decrease in specificity compared with the Dip group (67% vs 100%, P =.000001). CONCLUSIONS: Our data show that the addition of limited exercise to dipyridamole results in benefits during Tc-99m sestamibi imaging, increasing heart-to-liver activity ratio, preventing vasodilator-induced hypotension, and improving ECG sensitivity for the detection of ischemia. Furthermore, this protocol also provides an estimation of the patient's physical capacity and could be used as an alternative for patients undergoing dipyridamole infusion who are not completely unable to exercise.
Authors: R J Gibbons; G J Balady; J W Beasley; J T Bricker; W F Duvernoy; V F Froelicher; D B Mark; T H Marwick; B D McCallister; P D Thompson; W L Winters; F G Yanowitz; J L Ritchie; R J Gibbons; M D Cheitlin; K A Eagle; T J Gardner; A Garson; R P Lewis; R A O'Rourke; T J Ryan Journal: J Am Coll Cardiol Date: 1997-07 Impact factor: 24.094
Authors: J Lette; J L Tatum; S Fraser; D D Miller; D D Waters; G Heller; E B Stanton; H S Bom; J Leppo; S Nattel Journal: J Nucl Cardiol Date: 1995 Jan-Feb Impact factor: 5.952
Authors: T Sharir; B Rabinowitz; S Livschitz; I Moalem; J Baron; E Kaplinsky; P Chouraqui Journal: J Am Coll Cardiol Date: 1998-06 Impact factor: 24.094
Authors: D Daou; D Le Guludec; M Faraggi; J M Foult; R Lebtahi; A Cohen-Solal; P Assayag; G Steg Journal: Am J Cardiol Date: 1995-10-15 Impact factor: 2.778
Authors: G J Laarman; M G Niemeyer; E E van der Wall; F J Verzijlbergen; T L Go; A V Bruschke; C A Ascoop Journal: Int J Cardiol Date: 1988-08 Impact factor: 4.164
Authors: Alan W Ahlberg; Sarkis B Baghdasarian; Haris Athar; Jeffrey P Thompsen; Deborah M Katten; Gavin L Noble; Igor Mamkin; Anuj R Shah; Ivette A Leka; Gary V Heller Journal: J Nucl Cardiol Date: 2008 Jan-Feb Impact factor: 5.952
Authors: Matthew W Parker; Donna Chelle Morales; Hanna B Slim; Alan W Ahlberg; Deborah M Katten; Giselle Cyr; Shishir Mathur; Afrooz Ardestani; Dimitrios Barmpouletos; Geeta Swamy Iyah; Steven M Borer; Gary V Heller Journal: J Nucl Cardiol Date: 2012-11-28 Impact factor: 5.952
Authors: Randall C Thompson; Harshal Patil; Elaine C Thompson; Gregory S Thomas; Mohammed Al-Amoodi; Kevin F Kennedy; Kevin A Bybee; A Iain McGhie; James H O'Keefe; Lisa Oakes; Timothy M Bateman Journal: J Nucl Cardiol Date: 2012-12-12 Impact factor: 5.952
Authors: Milena J Henzlova; W Lane Duvall; Andrew J Einstein; Mark I Travin; Hein J Verberne Journal: J Nucl Cardiol Date: 2016-06 Impact factor: 5.952